The online version of this article (https://doi.org/10.1186/s12876-017-0736-0) contains supplementary material, which is available to authorized users.
Pathogenesis in non-alcoholic steatohepatitis (NASH) involves abnormal cholesterol metabolism and hepatic accumulation of toxic free cholesterol. Apical sodium-dependent bile acid transporter (ASBT) inhibition in the terminal ileum may facilitate removal of free cholesterol from the liver by reducing recirculation of bile acids (BAs) to the liver, thereby stimulating new BA synthesis from cholesterol. The aim of this phase 1 study in adult healthy volunteers (HVs) and patients with type 2 diabetes mellitus (T2DM) was to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of ASBT inhibition with volixibat (SHP626; formerly LUM002).
Participants were randomised 3:1 to receive once-daily oral volixibat (0.5 mg, 1 mg, 5 mg or 10 mg) or placebo for 28 days in two cohorts (HV and T2DM). Assessments included safety, faecal BA and serum 7α-hydroxy-4-cholesten-3-one (C4; BA synthesis biomarker).
Sixty-one individuals were randomised (HVs: placebo, n = 12; volixibat, n = 38; T2DM: placebo, n = 3; volixibat, n = 8). No deaths or treatment-related serious adverse events were reported. Mild or moderate gastrointestinal adverse events were those most frequently reported with volixibat. With volixibat, mean total faecal BA excretion on day 28 was ~1.6–3.2 times higher in HVs (643.73–1239.3 μmol/24 h) and ~8 times higher in T2DM (1786.0 μmol/24 h) than with placebo (HVs: 386.93 μmol/24 h; T2DM: 220.00 μmol/24 h). With volixibat, mean C4 concentrations increased by ~1.3–5.3-fold from baseline to day 28 in HVs and by twofold in T2DM.
Volixibat was generally well tolerated. Increased faecal BA excretion and serum C4 levels support the mechanistic rationale for exploring ASBT inhibition in NASH. The study was registered with the Dutch clinical trial authority (Centrale Commissie Mensgebonden Onderzoek; trial registration number NL44732.056.13; registered 24 May 2013).
Additional file 1: Complete inclusion and exclusion criteria. (DOCX 44 kb)12876_2017_736_MOESM1_ESM.docx
Additional file 2: Table S1. Glucose metabolism parameters in patients with type 2 diabetes mellitus. (DOCX 67 kb)12876_2017_736_MOESM2_ESM.docx
Additional file 3: Table S2. Glucose–insulin metabolism pharmacodynamic parameters in patients with type 2 diabetes mellitus. (DOCX 43 kb)12876_2017_736_MOESM3_ESM.docx
LaBrecque DR, Abbas Z, Anania F, Ferenci P, Khan AG, Goh KL, et al. World gastroenterology organisation global guidelines: nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. J Clin Gastroenterol. 2014;48:467–73. PubMed
Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2011;140:124–31. CrossRefPubMed
Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55:2005–23. CrossRefPubMed
Fassio E, Alvarez E, Dominguez N, Landeira G, Longo C. Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. Hepatology. 2004;40:820–6. PubMed
National Cholesterol Education Program Expert Panel. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation. 2002;106:3143–421.
Lau E, Carvalho D, Freitas P. Gut microbiota: association with NAFLD and metabolic disturbances. Biomed Res Int. 2015; https://doi.org/10.1155/2015/979515.
European Association for the Study of the Liver, European Association for the Study of Diabetes, European Association for the Study of Obesity. EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64:1388–402.
Carvalhana S, Cortez-Pinto H. From obesity to fatty liver/NASH: two parallel epidemics. In: Electronic World Gastroenterology News: the official e-newsletter of the World Gastroenterology Organisation; 2013. http://www.worldgastroenterology.org/publications/e-wgn/e-wgn-expert-point-of-view-articles-collection/from-obesity-to-fatty-livernash-two-parallel-epidemics. Accessed 20 Jul 2016.
Banini BA. Nonalcoholic steatohepatitis (NASH) has surpassed hepatitis C as the leading etiology for listing for liver transplant: implications for NASH in children and young adults. Las Vegas: American College of Gastroenterology Annual Scientific Meeting; 2016. (14–19 Oct 2016) Congress abstract 46. https://www.eventscribe.com/2016/ACG/QRcode.asp?Pres=199366. Accessed 20 Dec 2016
Schmitz G, Torzewski M, Barlage S, Drobnik W. Atherosclerosis. In: Keri G, Istvan T, editors. Molecular pathomechanisms and new trends in drug research. London; New York: Taylor & Francis; 2003. p. 413–57.
Gedulin B, Nikoulina S, Gedulin N, Nazarenkov B, Keller B. Apical sodium-dependent bile acid transport inhibitors (ASBTi) exhibit potent antidiabclic activity in ZDF rats. Diabetologia. 2013;56:S400–1.
Rao A, Kosters A, Mells JE, Zhang W, Setchell KDR, Amanso AM, et al. Inhibition of ileal bile acid uptake protects against nonalcoholic fatty liver disease in high-fat diet-fed mice. Sci Transl Med. 2016; https://doi.org/10.1126/scitranslmed.aaf4823.
Palmer M, Jennings L, Silberg D, Bliss C, Martin P. Volixibat, a minimally absorbed, oral, apical sodium-dependent bile acid transporter (ASBT) inhibitor, increases bile acid excretion, reduces serum lipids, is safe and tolerable in overweight and obese subjects, a population characteristic of NASH. Hepatology. 2016;64:574A. (Abstract 1139)
- Safety, tolerability and pharmacodynamics of apical sodium-dependent bile acid transporter inhibition with volixibat in healthy adults and patients with type 2 diabetes mellitus: a randomised placebo-controlled trial
Renger G. Tiessen
Ciara A. Kennedy
Bradley T. Keller
Andre A. van Vliet
- BioMed Central
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
e.Med Kampagnen-Visual, Mail Icon II